XRCC5 and hepatocellular carcinoma: Its autoantibody, serum anti-Ku86, is significantly elevated in HCC patients compared with LC patients and decreased after surgical resection with a positive rate of 60.7% in small early-stage HCC with 90% specificity, whereas the sensitivities of AFP and PIVKA-II were 17.8 and 21.4%, respectively.